Keros Therapeutics Inc
KROS
View Detailed Chart
10.680USD
+0.070+0.66%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
204.94MMarket Cap
4.57P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.66%
5 Days
-4.98%
1 Month
-23.22%
6 Months
-32.49%
Year to Date
-47.54%
1 Year
-1.02%
View Detailed Chart
TradingKey Stock Score of Keros Therapeutics Inc
Currency: USD Updated: 2026-03-30Key Insights
Keros Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 51 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.29.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Keros Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Keros Therapeutics Inc Highlights
StrengthsRisks
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 161529.80% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 4.57, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 29.78M shares, decreasing 50.32% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.96K shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
23.286
Target Price
+119.47%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Keros Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Keros Therapeutics Inc Info
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Ticker SymbolKROS
CompanyKeros Therapeutics Inc
CEOSeehra (Jasbir)
Websitehttps://www.kerostx.com/
Related Instruments
+0.96%
+1.56%
+0.85%
+2.90%
-1.28%
+1.78%
+1.47%
+0.07%
+0.00%
+2.70%
-2.08%
-0.13%
+0.72%
+2.03%
+2.33%
0.00%
+1.57%
-0.13%
+2.63%
+2.01%Popular Symbols
246.630
-2.170 (-0.87%)
165.170
-2.350 (-1.40%)
67657.060
+1035.660 (+1.55%)
251.670
-23.670 (-8.60%)
2063.140
+42.440 (+2.10%)
355.280
-6.550 (-1.81%)
4575.570
+64.790 (+1.44%)
101.971
-2.291 (-2.20%)
1.147
+0.000 (+0.03%)
159.602
-0.057 (-0.04%)
